Drug-Eluting Stents: Market Size & Forecast 2026

The global drug-eluting stent (DES) market sits at approximately USD 7.8 billion in 2025 (base year) on a 6.4% CAGR trajectory through 2032, with the category sitting in a structurally tight supplier-favored balance: a four-firm oligopoly holds an estimated 70-80% of revenue, second-generation durable-polymer and bioabsorbable-polymer technologies have replaced first-generation sirolimus-eluting Cypher-era designs, and the buyer side is constrained by long qualification cycles, single-supplier cath-lab vendor lists, and limited therapeutic substitution. Counterview: a 6.4% CAGR is at the upper edge of plausible for a mature implantable category with stable procedural volume; we read the consensus 7-8% as a touch optimistic and anchor our base case on a 6.4% midpoint with a 4-6% bear / 7-8% bull spread. > **Analyst Take.** the call is sequencing, not magnitude. Hospital procurement teams

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.